SYDNEXIS, INC.

SYDNEXIS, INC. has raised $21.0M in total funding. The most recent round was Series B.

SYDNEXIS, INC. is headquartered in Del Mar, CA.

Pediatric progressive myopia is the leading cause of vision loss in children, but current treatments like glasses only manage symptoms, and specialty contact lenses that slow progression aren't suitable for younger children.

Sydnexis is advancing a pharmaceutical approach intended to slow myopia progression at an early age, aiming to help preserve vision in growing eyes.

The company points to results from its SYD-101 'Star Study' and positions its pharmaceutical approach as addressing younger children specifically, a group current specialty lens options don't serve.

Raised a $45M Series B from RA Capital, Longitude Capital, Visionary Ventures and Bluestem Capital to develop a drug for pediatric myopia progression.